Neuroprotection in cardiosurgery
Acute stroke is one of the most important complications of corоnary artery bypass grafting surgery (CABG) and valve replacement in the setting of assisted circulation. Therefore the cerebralprotection becomes the crucial part of preoperative care. We performed prospective randomized controlled trial...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center of Neurology
2017-02-01
|
| Series: | Анналы клинической и экспериментальной неврологии |
| Subjects: | |
| Online Access: | https://annaly-nevrologii.com/journal/pathID/article/viewFile/386/280 |
| _version_ | 1818240572214738944 |
|---|---|
| author | Z. A. Suslina L. A. Bokeria M. A. Piradov A. I. Malashenkov N. A. Akhmadzhonuva P. A. Fedin Yu. V. Rodionova O. Yu. Rebrova M. V. Krotenkova A. V. Lagutin A. S. Klochkov |
| author_facet | Z. A. Suslina L. A. Bokeria M. A. Piradov A. I. Malashenkov N. A. Akhmadzhonuva P. A. Fedin Yu. V. Rodionova O. Yu. Rebrova M. V. Krotenkova A. V. Lagutin A. S. Klochkov |
| author_sort | Z. A. Suslina |
| collection | DOAJ |
| description | Acute stroke is one of the most important complications of corоnary artery bypass grafting surgery (CABG) and valve replacement in the setting of assisted circulation. Therefore the cerebralprotection becomes the crucial part of preoperative care. We performed prospective randomized controlled trial to estimate theefficacy of cytoflavin in 103 patients (94 men, 9 women) withischemic heart disease (ICD) and acquired valve disease whoundergone CABG and valve replacement surgery. The patientswere divided into 4 groups. Group 1 (main) consisted of 32 patients with ICD (mean age 55.77.9 years) who underwent CABGand received 20 ml of cytoflavin i.v. in 3 consecutive days beforeand 3 days after surgery. Group 2 (control) included 40 patientswith ICD (mean age 48.212.6 years) and CABG without cytoflavin. Thirteen patients with valve disease (mean age 53.18.4years) were randomized in Group 3 (main); they underwentvalve replacement and were treated with cytoflavin using thesame regimen (20 ml i.v. in 3 days before and 3 days after surgery). Group 4 (control) was comprised of 18 patients with valvedisease (mean age 48.212.0 years) and surgery without cerebralprotection with cytoflavin. One month after the intervention significant improvement (p0.05) was observed in Group 1 vs.Group 2 in the dynamic modality of cognitive performance,recent memory and long-term memory, and clear trend toimprovement in the same variables in Group 3 vs. Group 4.Moreover, in Group 2 (CABG without treatment) significantdeterioration was observed in long-term memory (p=0.028),along with the distinct trend towards worsening in Group 4 inrecent and long-term memory. As an effective antioxidant, cytoflavin renders reliable neuroprotective effect in patients whоunderwent CABG in the setting of assisted circulation andimproves cognitive functioning and emotional well-being. Cytoflavin ameliorates absolute characteristics of long-term andrecent memory in patients after valve replacement surgery. Cytoflavin improves absolute parameters of cognitive evoked potentials (P300) decreasing the latency and increasing the amplitude inpatients after CABG and valve replacement. Cytoflavin isrecommended for use in patients with ICD and acquired valvedisease who underwent CABG and valve replacement in the setting of assisted circulation. |
| first_indexed | 2024-12-12T13:15:34Z |
| format | Article |
| id | doaj.art-54c5af0af87c45ee8a88b1a41c5990db |
| institution | Directory Open Access Journal |
| issn | 2075-5473 2409-2533 |
| language | English |
| last_indexed | 2024-12-12T13:15:34Z |
| publishDate | 2017-02-01 |
| publisher | Research Center of Neurology |
| record_format | Article |
| series | Анналы клинической и экспериментальной неврологии |
| spelling | doaj.art-54c5af0af87c45ee8a88b1a41c5990db2022-12-22T00:23:25ZengResearch Center of NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-25332017-02-01314810.17816/psaic386280Neuroprotection in cardiosurgeryZ. A. Suslina0L. A. Bokeria1M. A. Piradov2A. I. Malashenkov3N. A. Akhmadzhonuva4P. A. Fedin5Yu. V. Rodionova6O. Yu. Rebrova7M. V. Krotenkova8A. V. Lagutin9A. S. Klochkov10Research Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Cardiovascular Surgery, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Cardiovascular Surgery, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowResearch Center of Neurology, Russian Academy of Medical Sciences, MoscowAcute stroke is one of the most important complications of corоnary artery bypass grafting surgery (CABG) and valve replacement in the setting of assisted circulation. Therefore the cerebralprotection becomes the crucial part of preoperative care. We performed prospective randomized controlled trial to estimate theefficacy of cytoflavin in 103 patients (94 men, 9 women) withischemic heart disease (ICD) and acquired valve disease whoundergone CABG and valve replacement surgery. The patientswere divided into 4 groups. Group 1 (main) consisted of 32 patients with ICD (mean age 55.77.9 years) who underwent CABGand received 20 ml of cytoflavin i.v. in 3 consecutive days beforeand 3 days after surgery. Group 2 (control) included 40 patientswith ICD (mean age 48.212.6 years) and CABG without cytoflavin. Thirteen patients with valve disease (mean age 53.18.4years) were randomized in Group 3 (main); they underwentvalve replacement and were treated with cytoflavin using thesame regimen (20 ml i.v. in 3 days before and 3 days after surgery). Group 4 (control) was comprised of 18 patients with valvedisease (mean age 48.212.0 years) and surgery without cerebralprotection with cytoflavin. One month after the intervention significant improvement (p0.05) was observed in Group 1 vs.Group 2 in the dynamic modality of cognitive performance,recent memory and long-term memory, and clear trend toimprovement in the same variables in Group 3 vs. Group 4.Moreover, in Group 2 (CABG without treatment) significantdeterioration was observed in long-term memory (p=0.028),along with the distinct trend towards worsening in Group 4 inrecent and long-term memory. As an effective antioxidant, cytoflavin renders reliable neuroprotective effect in patients whоunderwent CABG in the setting of assisted circulation andimproves cognitive functioning and emotional well-being. Cytoflavin ameliorates absolute characteristics of long-term andrecent memory in patients after valve replacement surgery. Cytoflavin improves absolute parameters of cognitive evoked potentials (P300) decreasing the latency and increasing the amplitude inpatients after CABG and valve replacement. Cytoflavin isrecommended for use in patients with ICD and acquired valvedisease who underwent CABG and valve replacement in the setting of assisted circulation.https://annaly-nevrologii.com/journal/pathID/article/viewFile/386/280coronary artery bypass grafting surgeryvalve replacementcerebral protection |
| spellingShingle | Z. A. Suslina L. A. Bokeria M. A. Piradov A. I. Malashenkov N. A. Akhmadzhonuva P. A. Fedin Yu. V. Rodionova O. Yu. Rebrova M. V. Krotenkova A. V. Lagutin A. S. Klochkov Neuroprotection in cardiosurgery Анналы клинической и экспериментальной неврологии coronary artery bypass grafting surgery valve replacement cerebral protection |
| title | Neuroprotection in cardiosurgery |
| title_full | Neuroprotection in cardiosurgery |
| title_fullStr | Neuroprotection in cardiosurgery |
| title_full_unstemmed | Neuroprotection in cardiosurgery |
| title_short | Neuroprotection in cardiosurgery |
| title_sort | neuroprotection in cardiosurgery |
| topic | coronary artery bypass grafting surgery valve replacement cerebral protection |
| url | https://annaly-nevrologii.com/journal/pathID/article/viewFile/386/280 |
| work_keys_str_mv | AT zasuslina neuroprotectionincardiosurgery AT labokeria neuroprotectionincardiosurgery AT mapiradov neuroprotectionincardiosurgery AT aimalashenkov neuroprotectionincardiosurgery AT naakhmadzhonuva neuroprotectionincardiosurgery AT pafedin neuroprotectionincardiosurgery AT yuvrodionova neuroprotectionincardiosurgery AT oyurebrova neuroprotectionincardiosurgery AT mvkrotenkova neuroprotectionincardiosurgery AT avlagutin neuroprotectionincardiosurgery AT asklochkov neuroprotectionincardiosurgery |